%A 陈邓林，陈俊民 %T 6-sulfo-LacNAc dendritic cells and tumors %0 Journal Article %D 2017 %J Journal of International Oncology %R 10.3760/cma.j.issn.1673-422X.2017.11.007 %P 834-837 %V 44 %N 11 %U {https://gjzlx.sdfmu.edu.cn/CN/abstract/article_10345.shtml} %8 2017-11-08 %X 6-sulfo-LacNAc dendritic cells (slanDCs), characterized by expressing the Fc receptors that absent in classic dendritic cells (DCs), have been identified as a novel subgroup of peripheral blood DCs. Hitherto, the majority researches of slanDCs are about inflammation and autoimmunity diseases, but a growing body of literature has shown that slanDCs may play important roles in antitumor immunity by inducing antibodydependent cellmediated cytotoxicity, releasing special cytokines, crosstalking with mesenchymal stem cells or natural killer cells, and signal transduction through Tolllike receptor pathway and mitogenactivated protein kinase pathway. slanDCs may be an ideal antitumor therapy tool.